<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Protein precursor of amyloid deposits</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Protein precursor of amyloid deposits</h1>
<div class="graphic"><div class="figure"><div class="ttl">Protein precursor of amyloid deposits</div><div class="cntnt"><table cellspacing="0"><colgroup span="3" width="20%"></colgroup><colgroup width="40%"></colgroup> <tbody> <tr> <td class="subtitle1">Protein class</td> <td class="subtitle1">Precursor protein (abbreviation)</td> <td class="subtitle1">Amyloid type</td> <td class="subtitle1">Clinical type</td> </tr> <tr> <td class="divider_bottom" rowspan="6">Apolipoproteins</td> <td>Serum amyloid A (SAA) protein</td> <td>AA</td> <td>Associated with amyloid complicating chronic infections or inflammatory diseases, and some heredofamilial periodic fever syndromes such as familial Mediterranean fever (FMF).</td> </tr> <tr> <td>Apolipoprotein A-I (ApoAI)</td> <td>AApoAI</td> <td>Age-related amyloid occurring in the aortic intima, and some hereditary neuropathic or cardiopathic <span style="white-space: nowrap;">amyloidoses.<sup>[1,2]</sup></span> May deposit in heart, liver, or kidney; C-terminal variants deposit in larynx and skin.</td> </tr> <tr> <td>Apolipoprotein A-II (ApoAII)</td> <td>AApoAII</td> <td>Some hereditary nephropathic <span style="white-space: nowrap;">amyloidoses.<sup>[3]</sup></span></td> </tr> <tr> <td>Apolipoprotein A-IV (ApoAIV)</td> <td>AApoAIV</td> <td>Renal (medullary) and cardiac <span style="white-space: nowrap;">amyloidosis.<sup>[4,5]</sup></span></td> </tr> <tr> <td>Apolipoprotein C-II (ApoCII)</td> <td>AApoCII</td> <td>Some hereditary nephropathic <span style="white-space: nowrap;">amyloidoses.<sup>[6]</sup></span></td> </tr> <tr class="divider_bottom"> <td>Apolipoprotein C-III (ApoCIII)</td> <td>AApoCIII</td> <td>Severe renal <span style="white-space: nowrap;">amyloidosis.<sup>[7]</sup></span></td> </tr> <tr> <td class="divider_bottom" rowspan="2">Immunoglobulin (Ig) gene superfamily</td> <td>Ig L chain/Ig H chains (IgL/IgH)</td> <td>AL/AH</td> <td>Primary and myeloma-associated amyloidosis. May be systemic or localized.</td> </tr> <tr class="divider_bottom"> <td>Beta-2 microglobulin</td> <td>Abeta2m</td> <td>Dialysis amyloidosis. Variant molecule has been described in a family affected by gastrointestinal disease, autonomic neuropathy, and sicca <span style="white-space: nowrap;">syndrome.<sup>[8]</sup></span></td> </tr> <tr> <td class="divider_bottom" rowspan="5">Neuroendocrine</td> <td>(Pro)Calcitonin</td> <td>ACal</td> <td> <p>Amyloid complicating C-cell thyroid tumors.</p> Renal amyloid.</td> </tr> <tr> <td> <p>Islet amyloid</p> Amylin</td> <td>AIAPP</td> <td>Islet cell amyloid in insulinomas, type II diabetes mellitus, and <span style="white-space: nowrap;">aging.<sup>[9]</sup></span></td> </tr> <tr> <td>Atrial natriuretic peptide</td> <td>AANF</td> <td>Isolated atrial amyloidosis of aging.</td> </tr> <tr> <td>Prolactin</td> <td>APro</td> <td>Prolactinomas, aging.</td> </tr> <tr class="divider_bottom"> <td>Insulin</td> <td>Alns</td> <td>Localized amyloid complicating use of the insulin pump.</td> </tr> <tr> <td class="divider_bottom" rowspan="3">Cytoskeleton related</td> <td>Gelsolin</td> <td>AGel</td> <td>Hereditary neuropathic amyloid associated with corneal lattice dystrophy and cutis laxa (Meretoja <span style="white-space: nowrap;">syndrome).<sup>[10]</sup></span></td> </tr> <tr> <td> <p>Keratin type I<br/> Cytoskeletal 14</p> Keratin type II<br/> Cytoskeletal 5</td> <td>Nomenclature to be revised</td> <td> <p>Lichen amyloidosis.</p> Macular amyloidosis.</td> </tr> <tr class="divider_bottom"> <td>Keratoepithelin</td> <td>AKer</td> <td>Hereditary granular, lattice, and Avellino corneal <span style="white-space: nowrap;">dystrophies.<sup>[11]</sup></span></td> </tr> <tr class="divider_bottom"> <td>Transport protein</td> <td>Transthyretin (TTR); also known as Prealbumin</td> <td>ATTR</td> <td>Hereditary neuropathic and/or cardiopathic amyloids; vitreous amyloidosis; leptomeningeal or renal amyloid in some kindreds; senile systemic <span style="white-space: nowrap;">amyloidosis.<sup>[12]</sup></span></td> </tr> <tr> <td class="divider_bottom" rowspan="4">Cerebrovascular/<br/> neurodegeneration</td> <td>Amyloid precursor protein (APP)</td> <td>Abeta</td> <td>Hereditary and sporadic Alzheimer disease; congophilic cerebral <span style="white-space: nowrap;">angiopathy.<sup>[13,14]</sup></span></td> </tr> <tr> <td>Prion protein (PRP)</td> <td>APrPsc</td> <td>Hereditary and sporadic spongiform <span style="white-space: nowrap;">encephalopathies.<sup>[15]</sup></span></td> </tr> <tr> <td>BRI gene product</td> <td>ABri/ADan</td> <td>Hereditary dementias (British and Danish <span style="white-space: nowrap;">types).<sup>[16,17]</sup></span></td> </tr> <tr class="divider_bottom"> <td>Cystatin C</td> <td>ACys</td> <td>Hereditary cerebrovascular hemorrhage with amyloidosis (Icelandic <span style="white-space: nowrap;">type).<sup>[18]</sup></span></td> </tr> <tr class="divider_bottom"> <td>Coagulation protein</td> <td>Fibrinogen A alpha chain</td> <td>AFib</td> <td>Hereditary nephropathic <span style="white-space: nowrap;">amyloidosis.<sup>[19]</sup></span></td> </tr> <tr class="divider_bottom"> <td>Enzyme</td> <td>Lysozyme</td> <td>ALys</td> <td>Hereditary nephropathic amyloidosis; may have marked hepatic, splenic, and gastrointestinal amyloid <span style="white-space: nowrap;">deposits.<sup>[19]</sup></span></td> </tr> <tr class="divider_bottom"> <td>Lung surfactant protein</td> <td>Lung surfactant protein</td> <td>ASPC</td> <td>Interstitial lung <span style="white-space: nowrap;">disease.<sup>[20]</sup></span></td> </tr> <tr> <td rowspan="10">Other</td> <td>Kerato-epithelin</td> <td>Aker</td> <td>Various familial corneal <span style="white-space: nowrap;">dystrophies.<sup>[11]</sup></span></td> </tr> <tr> <td>Lactoferrin</td> <td>ALac</td> <td>Corneal amyloidosis associated with trichiasis.</td> </tr> <tr> <td>Odontogenic ameloblast-associated protein</td> <td>AOAAP</td> <td>Calcifying epithelial odontogenic tumors (CEOTs).</td> </tr> <tr> <td>Semenogelin 1</td> <td>ASem1</td> <td>Senile seminal vesicle amyloid.</td> </tr> <tr> <td>Lactadherin</td> <td>AMed</td> <td>Senile aortic amyloid; media deposition.</td> </tr> <tr> <td>Leukocyte chemotactic factor 2</td> <td>ALect2</td> <td>Nephropathic or hepatic amyloid.</td> </tr> <tr> <td>Corneodesmosin</td> <td>ACor</td> <td>Localized amyloid involving cornified epithelia, hair follicles.</td> </tr> <tr> <td>Enfuvirtide</td> <td>AEnf</td> <td>Localized amyloid occurring at the injection site of an HIV <span style="white-space: nowrap;">therapeutic.<sup>[21]</sup></span></td> </tr> <tr> <td>Cathepsin K</td> <td>ACatK</td> <td>Tumor <span style="white-space: nowrap;">associated.<sup>[22]</sup></span></td> </tr> <tr> <td>Epithelial growth factor (EGF)-containing fibulin-like extracellular matrix protein 1 (EFEMP1)</td> <td>AEFEMP1</td> <td>Portal veins; age <span style="white-space: nowrap;">associated.<sup>[23]</sup></span></td> </tr> </tbody></table></div><div class="graphic_reference">References:

	<ol>
<li>Mucchiano GI, Haggqvist B, Sletten K, Westermark P. Apolipoprotein A-1-derived amyloid in atherosclerotic plaques of the human aorta. J Pathol 2001; 193:270.</li>
<li>de Sousa MM, Vital C, Ostler D, et al. Apolipoprotein AI and transthyretin as components of amyloid fibrils in a kindred with apoAI Leu178His amyloidosis. Am J Pathol 2000; 156:1911.</li>
<li>Benson MD, Liepnieks JJ, Yazaki M, et al. A new human hereditary amyloidosis: the result of a stop-codon mutation in the apolipoprotein AII gene. Genomics 2001; 72:272.</li>
<li>Said SM, Sethi S, Valeri AM, et al. Renal amyloidosis: origin and clinicopathologic correlations of 474 recent cases. Clin J Am Soc Nephrol 2013; 8:1515.</li>
<li>Bois MC, Dasari S, Mills JR, et al. Apolipoprotein A-IV-associated cardiac amyloidosis. J Am Coll Cardiol 2017; 69:2248.</li>
<li>Nasr SH, Dasari S, Hasadsri L, et al. Novel type of renal amyloidosis derived from apolipoprotein-CII. J Am Soc Nephrol 2016.</li>
<li>Valleix S, Verona G, Jourde-Chiche N, et al. D25V apolipoprotein C-III variant causes dominant hereditary systemic amyloidosis and confers cardiovascular protective lipoprotein profile. Nat Commun 2016; 7:10353.</li>
<li>Valleix S, Gillmore JD, Bridoux F, et al. Hereditary systemic amyloidosis due to Asp76Asn variant β2-microglobulin. N Engl J Med 2012; 366:2276.</li>
<li>Höppener JW, Ahrén B, Lips CJ. Islet amyloid and type 2 diabetes mellitus. N Engl J Med 2000; 343:411.</li>
<li>Kiuru S. Gelsolin-related familial amyloidosis, Finnish type (FAF), and its variants found worldwide. Amyloid 1998; 5:55.</li>
<li>Klintworth GK. The molecular genetics of the corneal dystrophies--current status. Front Biosci 2003; 8:d687.</li>
<li>Connors LH, Lom A, Prokaeva T, et al. Tabulation of human transthyretin (TTR) variants, 2003. Amyloid 2003; 10:160.</li>
<li>Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Revs 2001; 81:741.</li>
<li>Revesz T, Ghiso J, Lashley T, et al. Cerebral amyloid angiopathies: a pathologic, biochemical, and genetic view. J Neuropathol Exp Neurol 2003; 62:885.</li>
<li>Prusiner SB. Shattuck lecture--neurodegenerative diseases and prions. N Engl J Med 2001; 344:1516.</li>
<li>Vidal R, Frangione B, Rostagno A, et al. A stop-codon mutation in the BRI gene associated with familial British dementia. Nature 1999; 399:776.</li>
<li>Gibson G, Gunasekera N, Lee M, et al. Oligomerization and neurotoxicity of the amyloid ADan peptide implicated in familial Danish dementia. J Neurochem 2004; 88:281.</li>
<li>Olafsson I, Grubb A. Hereditary cystatin C amyloid angiopathy. Amyloid 2000; 7:70.</li>
<li>Hawkins PN. Hereditary systemic amyloidosis with renal involvement. J Nephrol 2003; 16:443.</li>
<li>Willander H, Askarieh G, Landreh M, et al. High-resolution structure of a BRICHOS domain and its implications for anti-amyloid chaperone activity on lung surfactant protein C. Proc Natl Acad Sci U S A 2012; 109:2325.</li>
<li>Naujokas A, Vidal CI, Mercer CE, et al. A novel form of amyloid deposited at the site of enfuvirtide injection. J Cutan Pathol 2012; 39:220.</li>
<li>Linke RP, Serpell LC, Lottspeich F, Toyoda M. Cathepsin K as a novel amyloid fibril protein in humans. Amyloid 2017; 24:68.</li>
<li>Dao LN, Kurtin PJ, Smyrk TC, et al. The novel form of amyloidosis derived from EGF-containing fibulin-like extracellular matrix protein 1 (EFEMP1) preferentially affects the lower gastrointestinal tract of elderly females. Histopathology 2021; 78:459.</li>
</ol>

	Adapted from: Benson MD, Buxbaum JN, Eisenberg DS, et al. Amyloid nomenclature 2020: Update and recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. Amyloid 2020; 27:217.</div><div id="graphicVersion">Graphic 97157 Version 5.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
